Human Osteoarthritic Cartilage Matrix Vesicles Generate Both Calcium Pyrophosphate Dihydrate and ApatiteIn Vitro

1998 ◽  
Vol 63 (3) ◽  
pp. 258-262 ◽  
Author(s):  
B. Derfus ◽  
S. Kranendonk ◽  
N. Camacho ◽  
N. Mandel ◽  
V. Kushnaryov ◽  
...  
Keyword(s):  
Matrix Vesicles ◽  
Calcium Pyrophosphate ◽  
Cartilage Matrix ◽  
Calcium Pyrophosphate Dihydrate ◽  
Osteoarthritic Cartilage ◽  
Pyrophosphate Dihydrate

Tumoral calcium pyrophosphate dihydrate deposition disease with bone destruction in the shoulder

1998 ◽  
Vol 39 (3) ◽  
pp. 269-272
Author(s):  
H. Mizutani ◽  
S. Ohba ◽  
M. Mizutani ◽  
S. Sasaki ◽  
K. Ando ◽  
...  
Keyword(s):  
Bone Destruction ◽  
Calcium Pyrophosphate ◽  
Calcium Pyrophosphate Dihydrate ◽  
Deposition Disease ◽  
Pyrophosphate Dihydrate

scholarly journals Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab

2021 ◽  
Vol 9 (7) ◽  
pp. e002716
Author(s):  
Sang T. Kim ◽  
Jean Tayar ◽  
Siqing Fu ◽  
Danxia Ke ◽  
Elliot Norry ◽  
...  
Keyword(s):  
T Cells ◽  
Synovial Fluid ◽  
Th17 Cells ◽  
Effector Cell ◽  
Calcium Pyrophosphate ◽  
Calcium Pyrophosphate Dihydrate ◽  
Immune Effector Cell ◽  
Cell Therapies ◽  
Immune Effector ◽  
Pyrophosphate Dihydrate

With durable cancer responses, genetically modified cell therapies are being implemented in various cancers. However, these immune effector cell therapies can cause toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Pseudogout arthritis is an inflammatory arthritis induced by deposition of calcium pyrophosphate dihydrate crystals. Here, we report a case of pseudogout arthritis in a patient treated with MAGE-A4 directed T cell receptor T cells, for fallopian tube cancer. The patient developed CRS and ICANS 7 days after infusion of the T cells. Concurrently, the patient newly developed sudden onset of left knee arthritis. Synovial fluid analyses revealed the presence of calcium pyrophosphate dihydrate crystal. Notably, the pseudogout arthritis was resolved with tocilizumab, which was administered for the treatment of CRS and ICANS. Immunoprofiling of the synovial fluid showed that the proportion of inflammatory interleukin 17 (IL-17)-producing CD4+ T (Th17) cells and amount of IL-6 were notably increased, suggesting a potential role of Th17 cells in pseudogout arthritis after T-cell therapy. To the best of our knowledge, this is the first reported case of pseudogout arthritis after cell therapy. Clinicians, especially hematologists, oncologists and rheumatologists, should be aware that pseudogout arthritis can be associated with CRS/ICANS.

scholarly journals Calcium Pyrophosphate Dihydrate Crystals Increase the Granulocyte/Monocyte Progenitor (GMP) and Enhance Granulocyte and Monocyte Differentiation In Vivo

2020 ◽  
Vol 22 (1) ◽  
pp. 262
Author(s):  
Nobuyuki Onai ◽  
Chie Ogasawara
Keyword(s):  
Cell Differentiation ◽  
Peripheral Blood ◽  
Calcium Pyrophosphate ◽  
Hematopoietic Progenitor Cell ◽  
Calcium Pyrophosphate Dihydrate ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Hematopoietic Stem ◽  
Cppd Crystal ◽  
Pyrophosphate Dihydrate

Calcium pyrophosphate dihydrate (CPPD) crystals are formed locally within the joints, leading to pseudogout. Although the mobilization of local granulocytes can be observed in joints where pseudogout has manifested, the mechanism of this activity remains poorly understood. In this study, CPPD crystals were administered to mice, and the dynamics of splenic and peripheral blood myeloid cells were analyzed. As a result, levels of both granulocytes and monocytes were found to increase following CPPD crystal administration in a concentration-dependent manner, with a concomitant decrease in lymphocytes in the peripheral blood. In contrast, the levels of other cells, such as dendritic cell subsets, T-cells, and B-cells, remained unchanged in the spleen, following CPPD crystal administration. Furthermore, an increase in granulocytes/monocyte progenitors (GMPs) and a decrease in megakaryocyte/erythrocyte progenitors (MEPs) were also observed in the bone marrow. In addition, CPPD administration induced production of IL-1β, which acts on hematopoietic stem cells and hematopoietic progenitors and promotes myeloid cell differentiation and expansion. These results suggest that CPPD crystals act as a “danger signal” to induce IL-1β production, resulting in changes in course of hematopoietic progenitor cell differentiation and in increased granulocyte/monocyte levels, and contributing to the development of gout.

The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease

2004 ◽  
Vol 71 (5) ◽  
pp. 365-368 ◽  
Author(s):  
Patrick Netter ◽  
Thomas Bardin ◽  
Arnaud Bianchi ◽  
Pascal Richette ◽  
Damien Loeuille
Keyword(s):  
Calcium Pyrophosphate ◽  
Calcium Pyrophosphate Dihydrate ◽  
Deposition Disease ◽  
Pyrophosphate Dihydrate

Massive Solitary Tophus Containing Calcium Pyrophosphate Dihydrate Crystals at the Acromioclavicular Joint

1988 ◽  
Vol &NA; (227) ◽  
pp. 305???309
Author(s):  
RALPH C. MARCOVE ◽  
SCOTT W. WOLFE ◽  
JOHN H. HEALEY ◽  
ANDREW G. HUVOS ◽  
ADELE BOSKEY ◽  
...  
Keyword(s):  
Acromioclavicular Joint ◽  
Calcium Pyrophosphate ◽  
Calcium Pyrophosphate Dihydrate ◽  
Pyrophosphate Dihydrate ◽  
Calcium Pyrophosphate Dihydrate Crystals
Sign in / Sign up

Export Citation Format

Share Document